Progressive anticonvulsant hypersensitivity syndrome associated with change of drug product.
This report describes the laboratory and physical manifestations of lamotrigine-like toxicity in a young man with refractory epilepsy receiving lamotrigine presenting as anticonvulsant hypersensitivity syndrome (AHS) associated with an abrupt change of drug product.
Sabroe
T P
TP
Department of Chemical Process Development, LEO Pharma, Ballerup, Denmark. thomas.sabroe@leo-pharma.com <thomas.sabroe@leo-pharma.com>
Sabers
A
A
D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D018771:Arthralgia / Q000139:chemically induced; D001168:Arthritis / Q000139:chemically induced; D016568:Drugs, Generic / Q000009:adverse effects* / Q000627:therapeutic use; D004827:Epilepsy / Q000188:drug therapy*; D005076:Exanthema / Q000139:chemically induced; D005334:Fever / Q000139:chemically induced; D006801:Humans; D000077213:Lamotrigine; D008297:Male; D009135:Muscular Diseases / Q000139:chemically induced; D010612:Pharyngitis / Q000139:chemically induced; D011014:Pneumonia / Q000139:chemically induced; D013577:Syndrome; D014227:Triazines / Q000009:adverse effects* / Q000627:therapeutic use
D000927:Anticonvulsants; D016568:Drugs, Generic; D014227:Triazines; D000077213:Lamotrigine